Dr. Gross is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
USC Norris Cancer Hospital/ Westside Cancer Center
9033 Wilshire Blvd, Suite 300
Beverly Hills, CA 90211Phone+1 310-272-7640Fax+1 310-272-7656- Is this information wrong?
Summary
- Dr. Mitchell Gross is an oncologist in Beverly Hills, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, Cedars-Sinai Medical Center, USC Norris Comprehensive Cancer Center, and LAC+USC Medical Center. He received his medical degree from Baylor College of Medicine and has been in practice 23 years. He specializes in genitourinary oncology and hematologic oncology and is experienced in prostate cancer, urologic oncology, bladder cancer, testicular cancer, and pediatric urologic oncology.
Education & Training
- UCLA, College of Letters and SciencePh.D, Molecular Biolog, 2003
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2002
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1994 - 1997
- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1994 - 1995
- Baylor College of MedicineClass of 1994
- University of California BA, Biochemistry/Cell Biology, 1990
Certifications & Licensure
- CA State Medical License 1996 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Specialty Training Research Fellowship 1997-2222, 2002
- AACR-AFLAC Scholar in Training Award 2001
- Amgen Fellowship Research Award 1999
- Join now to see all
Clinical Trials
- Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer Start of enrollment: 2010 Feb 17
- A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer Start of enrollment: 2008 Apr 01
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsEffect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial.Jacqueline K. Dawson, Tanya B. Dorff, Creighton T. Tuzon, Judd C. Rice, E T. Schroeder, Christianne J. Lane, Mitchell E. Gross, Christina M. Dieli-Conwright> ;Integrative Cancer Therapies. 2021 Jul 23
- 21 citationsCCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation.Noah Trac, Leng-Ying Chen, Ailin Zhang, Chun-Peng Liao, Christopher Poon, Jonathan Wang, Yuta Ando, Johan Joo, Carolina Garri, Keyue Shen, Kian Kani, Mitchell E. Gross...> ;Journal of Controlled Release. 2021 Jan 10
- 30 citationsPhase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer.Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek Pinski, David I. Quinn, Olga O. Castellanos, Patrick O. Gilmore, Jean C. Shih> ;Prostate Cancer and Prostatic Diseases. 2021 Mar 1
- Join now to see all
Journal Articles
- Role of AUUU sequences in stabilization of granuclocyte-macrophage colony-stimulating factor RNA in stimulated cells.Akashi M., Shaw G., Gross M., Saito M., Koeffler H.P, Blood. 78:2005-12.
- Lack of effect of clinical research protocol participation on morbidity measures in HIV-infected children.Gross M.E., Smith E.O., Kline M.W, Ped. Infect Dis.J. 12:157-8
- Antimicrobial activities of beta-lactam antibiotics and gentamycin against penicillin-susceptible and penicillin-resistant pneumococci.Gross M.E., Giron K.P., Septimus J.D., Mason E.O., Musher D.M, Antimicro Agents Chemo. 39:1166-8
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Androgen receptor and estrogen receptor-beta associates with Gleason score, but not obesity in prostate cancer.Mitchell E, American Urological Association, Anaheim, California
- Raloxifene, a selective estrogen receptor modulator, for the treatment of androgen independent prostate cancer (AIPC).Cinman, N., Aronson, N., Shazer, R., Nguyen, K.N., Nguyen, H.H.T., Bender, L., Green, L., Gross, M., Kaplan, L.M., Natale, R. B., Agus, D.B, ASCO Molecular Therapeutics Symposium. Abstract #80
- A Proteomic Approach to Identify Whole Proteins Induced by Androgens, Estradiol, and IL-6 in prostate cancer cells.Top, I., Katz, J., Damoiseaxu, R., Agus, D., Gross, M, Proc. Amer. Assoc. Cancer Research, Abstract 3095
- Join now to see all
Lectures
- Update on Prostate Cancer.Los Angeles, California, 2007, 2008
- Drug Development Series, Targeted Bone Therapy for Prostate Cancer.UT San Antonio Health Sciences Cente
- Hematology-Oncology Grand Rounds.Cedars Sinai Medical Center, Los Angeles, California
- Join now to see all
Press Mentions
- Antidepressant May Improve Prostate Cancer OutcomesMarch 4th, 2020
Professional Memberships
- Member
Hospital Affiliations
- Keck Hospital of USCLos Angeles, California
- Cedars-Sinai Medical CenterLos Angeles, California
- USC Norris Comprehensive Cancer CenterLos Angeles, California
- Los Angeles General Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: